Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.

Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301 · see citing works

Which GABAA-receptor subtypes really occur in the brain?

McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222 · see citing works

Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172 · see citing works

Molecular and neuronal substrate for the selective attenuation of anxiety

Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · see citing works

Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype

McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944 · see citing works

Subunit Composition, Distribution and Function of GABA-A Receptor Subtypes

Sieghart, W., & Sperk, G. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393507 · Cited by 914 · see citing works

Clinical Pharmacokinetics of Oxazepam and Lorazepam

Greenblatt, D. J. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106020-00001 · Cited by 368 · see citing works

Compartmental Analysis of [ 11 C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography

Koeppe, R. A., Holthoff‐Detto, V., Frey, K. A., Kilbourn, M. R., & Kuhl, D. E. (1991) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1991.130 · Cited by 347 · see citing works

Structure, Pharmacology, and Function of GABAA Receptor Subtypes

Sieghart, W. (2006) · Advances in pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 321 · see citing works

Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia

Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K. E., Förster, S., Kelly, M. A., & Montrose, D. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 286 · see citing works

Evidence for a Significant Role of α3-Containing GABA_AReceptors in Mediating the Anxiolytic Effects of Benzodiazepines

Dias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247 · see citing works

The benzodiazepine binding site of GABAAreceptors as a target for the development of novel anxiolytics

Atack, J. R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.5.601 · Cited by 194 · see citing works

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188 · see citing works

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA A α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

de Haas, S. L., de Visser, S. J., Post, J. P. V. D., Schoemaker, R. C., Dyck, K. V., Murphy, M. G., Smet, M. D., Vessey, L. K., Ramakrishnan, R., Xue, L., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107082108 · Cited by 104 · see citing works

Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat

Lister, R. G., Greenblatt, D. J., Abernethy, D. R., & File, S. E. (1984) · Brain Research · doi:10.1016/0006-8993(84)90752-2 · Cited by 88 · see citing works

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA _A α _2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · see citing works

Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo

Greenblatt, D. J., Harmatz, J. S., Dorsey, C. M., & Shader, R. I. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.158 · Cited by 74 · see citing works

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers

de Haas, S., Franson, K. L., Schmitt, J. A. J., Cohen, A., Fau, J., Dubruc, C., & van Gerven, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108092595 · Cited by 68 · see citing works

Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 Subtypes

Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66 · see citing works

Preclinical and clinical pharmacology of TPA023B, a GABA A receptor α2/α3 subtype-selective partial agonist

Atack, J. R., Hallett, D. J., Tye, S. J., Wafford, K. A., Ryan, C. N., Bohorquez, S. M. S., Eng, W., Gibson, R., Burns, H. D., Dawson, G., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109354928 · Cited by 63 · see citing works

MRK-409 (MK-0343), a GABA A receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans

Atack, J. R., Wafford, K. A., Street, L. O. N. D. O. N. G., Dawson, G., Tye, S. J., Laere, K. V., Bormans, G. M., Bohorquez, S. M. S., Lepeleire, I. D., de Hoon, J., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109354927 · Cited by 60 · see citing works

Contributions of GABA_AReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders

Ator, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59 · see citing works

SL651498: An Anxioselective Compound with Functional Selectivity for α2- and α3-Containing γ-Aminobutyric AcidA (GABAA) Receptors

Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59 · see citing works

7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H -1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3- b ]pyridazine: A Functionally Selective γ-Aminobutyric Acid A (GABA A ) α2/α3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models

Carling, R. W., Madin, A., Guiblin, A., Russell, M. G. N., Moore, K. W., Mitchinson, A., Sohal, B., Pike, A. J., Cook, S. M., Ragan, I., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058034a · Cited by 54 · see citing works

Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography

Shinotoh, H., Iyo, M., Yamada, T., Inoue, O., Suzuki, K., Itoh, T., Fukuda, H., Yamasaki, T., Tateno, Y., & Hirayama, K. (1989) · Psychopharmacology · doi:10.1007/bf00442808 · Cited by 52 · see citing works

Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans

Fujita, M., Woods, S. W., Verhoeff, N. P. L. G., Abi‐Dargham, A., Baldwin, R. M., Zoghbi, S. S., Soares, J. C., Jatlow, P. A., Krystal, J. H., Rajeevan, N., et al. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00013-8 · Cited by 46 · see citing works

Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography

Abadie, P., Rioux, P. P., Scatton, B., Zarifian, E., Barré, L., Patat, A. A., & Baron, J. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00633-8 · Cited by 46 · see citing works

Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo

Malizia, A. L., Gunn, R. N., Wilson, S. J., Waters, S., Bloomfield, P. M., Cunningham, V. J., & Nutt, D. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00072-x · Cited by 45 · see citing works

[123I]Iomazenil spect imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain

Sybirska, E. H., Seibyl, J. P., Bremner, J. D., Baldwin, R. M., Al‐Tikriti, M. S., Bradberry, C. W., Malison, R. T., Zea‐Ponce, Y., Zoghbi, S. S., During, M. J., et al. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90080-m · Cited by 42 · see citing works

Benzodiazepine receptor equilibrium constants for flumazenil and midazolam determined in humans with the single photon emission computer tomography tracer [123I]iomazenil

Videæk, C., Friberg, L., Holm, S., Wammen, S., Foged, C., Andersen, J. V., Dalgaard, L., & Lassen, N. A. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90660-a · Cited by 35 · see citing works

A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist

Lingford-Hughes, A. R., Wilson, S. J., Feeney, A., Grasby, P. M., & Nutt, D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0060-1 · Cited by 29 · see citing works

A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines

McBride, B. J., Baldwin, R. M., Kerr, J. M., & Wu, J.-L. (1991) · International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes · doi:10.1016/0883-2889(91)90069-d · Cited by 29 · see citing works

In vivo labelling of α5 subunit-containing GABA receptors using the selective radioligand [H]L-655,708

Atack, J. R., Alder, L., COOK, S., SMITH, A., & McKernan, R. M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.004 · Cited by 27 · see citing works

In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2/α3/α5 Subtype Selective γ-Aminobutyric Acid–A Partial Agonist

Laere, K. V., Bormans, G. M., Bohorquez, S. M. S., de Groot, T., Dupont, P. J., Lepeleire, I. D., Hoon, J. N. J. M. D., Mortelmans, L. A., Hargreaves, R. J., Atack, J. R., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.021 · Cited by 23 · see citing works

The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone

Atack, J. R., Pike, A., Marshall, G. R., Stanley, J. L., Lincoln, R. J., Cook, S. M., Lewis, R. T., Blackaby, W., Goodacre, S. C., McKernan, R. M., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.014 · Cited by 18 · see citing works

The plasma–occupancy relationship of the novel GABAAreceptor benzodiazepine site ligand, α5IA, is similar in rats and primates

Atack, J. R., Eng, W., Gibson, R. E., Ryan, C. N., Francis, B. E., Sohal, B., Dawson, G. R., Hargreaves, R. J., & Burns, H. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00216.x · Cited by 16 · see citing works

Comparison of Lorazepam [7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2 H-1,4-benzodiazepin-2-one] Occupancy of Rat Brain γ-Aminobutyric AcidA Receptors Measured Using in Vivo [3H]Flumazenil (8-Fluoro 5,6-dihydro-5-methyl-6-oxo-4 H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester) Binding and [11C]Flumazenil Micro-Positron Emission Tomography

Atack, J. R., Scott‐Stevens, P., Beech, J. S., Fryer, T. D., Hughes, J. L., Cleij, M. C., Baron, J., Clark, J. C., Hargreaves, R. J., & Aigbirhio, F. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114884 · Cited by 15 · see citing works

A new human (psycho)pharmacology tool: the multiple organs coincidences counter (MOCC)

Malizia, A. L., Forse, G. R., Haida, A., Gunn, R. N., Melichar, J., Poole, K., Bateman, D. M., Fahy, D., Schnorr, L., Brown, D., et al. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900402 · Cited by 14 · see citing works

Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET

Pauli, S., Farde, L., Halldin, C., & Sedvall, G. (1991) · European Neuropsychopharmacology · doi:10.1016/0924-977x(91)90498-j · Cited by 13 · see citing works

Discrepancy of benzodiazepine receptor occupancy between 3 H-flumazenil and 125 I-iomazenil in intact mouse brain

Hosoi, R., Kobayashi, K., Watanabe, Y., & Inoue, O. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050154 · Cited by 9 · see citing works

International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans

Sieghart, W., & Savić, M. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014449 · Cited by 211 · see citing works

Small-animal positron emission tomography as a tool for neuropharmacology

Lancelot, S., & Zimmer, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.002 · Cited by 122 · see citing works

GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors

Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 89 · see citing works

An Historical Perspective on Gabaergic Drugs

Froestl, W. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.10.285 · Cited by 89 · see citing works

Discovery of allosteric modulators for GABAA receptors by ligand-directed chemistry

Yamaura, K., Kiyonaka, S., Numata, T., Inoue, R., & Hamachi, I. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2150 · Cited by 80 · see citing works

Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update

Maramai, S., Benchekroun, M., Ward, S. E., & Atack, J. R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01312 · Cited by 75 · see citing works

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

Nickolls, S. A., Gurrell, R., van Amerongen, G., Kammonen, J., Cao, L., Brown, A. R., Stead, C., Mead, A. N., Watson, C. A., Hsu, C. C., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14119 · Cited by 62 · see citing works

Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023

Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · see citing works

A question of balance – Positive versus negative allosteric modulation of GABAA receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain

Munro, G., Erichsen, H. K., Rae, M. G., & Mirza, N. R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.017 · Cited by 51 · see citing works

The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

Witkin, J. M., Lippa, A., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173321 · Cited by 48 · see citing works

Modeling of PET data in CNS drug discovery and development

Varnäs, K., Varrone, A., & Farde, L. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9320-6 · Cited by 44 · see citing works

Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023

Castner, S. A., Arriza, J. L., Roberts, J. C., Mrzljak, L., Christian, E. P., & Williams, G. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.001 · Cited by 37 · see citing works

Design and identification of a novel, functionally subtype selective GABAApositive allosteric modulator (PF-06372865).

Owen, R. M., Blakemore, D. C., Cao, L., Flanagan, N. J., Fish, R. L., Gibson, K. R., Gurrell, R., Huh, C. W., Kammonen, J., Mortimer‐Cassen, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00322 · Cited by 36 · see citing works

GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085

de Lucas, A. G., Ahring, P. K., Larsen, J. S., Rivera-Arconada, I., Lopez-Garcia, J. A., Mirza, N. R., & Munro, G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.010 · Cited by 32 · see citing works

Mechanistic models enable the rational use ofin vitrodrug-target binding kinetics for better drug effects in patients

de Witte, W. E. A., Wong, Y. C., Nederpelt, I., Heitman, L. H., Danhof, M., van der Graaf, P. H., Gilissen, R., & de Lange, E. C. M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1100163 · Cited by 32 · see citing works

GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans

Jučaitė, A., Cselényi, Z., Lappalainen, J., McCarthy, D. J., Lee, C., Nyberg, S., Varnäs, K., Stenkrona, P., Halldin, C., Cross, A. J., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4506-4 · Cited by 32 · see citing works

A Comparison of the 2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain

Nickolls, S. A., Mace, H., Fish, R. L., Edye, M. E., Gurrell, R., Ivarsson, M., Pitcher, T., Tanimoto-Mori, S., Richardson, D. S., Sweatman, C., et al. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/608912 · Cited by 29 · see citing works

Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects

Raddad, E., Chappell, A. S., Meyer, J. H., Wilson, A. A., Ruegg, C. E., Tauscher, J. T., Statnick, M. A., Barth, V., Zhang, X., & Verfaille, S. J. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070359 · Cited by 27 · see citing works

Development of Antipsychotic Medications with Novel Mechanisms of Action Based on Computational Modeling of Hippocampal Neuropathology

Siekmeier, P. J., & vanMaanen, D. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058607 · Cited by 23 · see citing works

Multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated 18F-fluorination

Gendron, T., Destro, G., Straathof, N. J. W., Sap, J. B. I., Guibbal, F., Vriamont, C., Caygill, C. H., Atack, J. R., Watkins, A. J., Marshall, C., et al. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00158-z · Cited by 22 · see citing works

The effects of TPA023, a GABA A α 2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol

de Haas, S., Zoethout, R., Dyck, K. V., Smet, M. D., Rosen, L., Murphy, M., Gottesdiener, K., Schoemaker, R. C., Cohen, A., & van Gerven, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111415731 · Cited by 20 · see citing works

Occupancy of human brain GABAA receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [11C]flumazenil PET imaging

Eng, W., Atack, J. R., Bergström, M., Sanabria, S., Appel, L., Dawson, G. R., Sciberras, D. G., Hargreaves, R. J., Långström, B., & Burns, H. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.024 · Cited by 20 · see citing works

Indications of success: Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development

Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 19 · see citing works

Translation of Central Nervous System Occupancy from Animal Models: Application of Pharmacokinetic/Pharmacodynamic Modeling

Melhem, M. R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199794 · Cited by 18 · see citing works

Development of Subtype-Selective GABAA Receptor Compounds for the Treatment of Anxiety, Sleep Disorders and Epilepsy

Atack, J. R. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_2 · Cited by 18 · see citing works

Positive allosteric modulation of GABA-A receptors reduces capsaicin-induced primary and secondary hypersensitivity in rats

Hansen, R. R., Erichsen, H. K., Brown, D. T., Mirza, N. R., & Munro, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.002 · Cited by 13 · see citing works

GABA and Sleep: Molecular, Functional and Clinical Aspects

Reite, M. L. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010133 · Cited by 11 · see citing works

Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies

Jankowska, A., Satała, G., Partyka, A., Wesołowska, A., Bojarski, A. J., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190710172002 · Cited by 10 · see citing works

Antimicrobial Activities of Novel 3-Substituted [1,2,4] Triazolo[4,3-b]pyridazines Derivatives

Ruso, J. S., Rajendiran, N., Chowdappa, S., Murthy, K. N., & Soumya, K. (2014) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2014.58.4.377 · Cited by 9 · see citing works

Nonsedating anxiolytics

Cerne, R., Smith, J. L., Chrzanowska, A., & LIPPA, A. S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173895 · Cited by 7 · see citing works

Oxidative Cyclisation Based One-Pot Synthesis of 3-Substituted[1,2,4]triazolo[4,3-b]pyridazines Using Me4NBr/Oxone

Ruso, J. S., Nagappan, R., & Kumaran, R. S. (2013) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2013.57.5.606 · Cited by 7 · see citing works

Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography

Johnström, P., Fryer, T. D., Bird, J., Richards, H. K., & Davenport, A. P. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-909-9_11 · Cited by 4 · see citing works

Imaging Techniques for Central Nervous System (CNS) Drug Discovery

Zhang, L., & Villalobos, A. (2015) · doi:10.1002/9781118788523.ch17 · Cited by 3 · see citing works

Pharmacological principles for safe benzodiazepine and Z-drug dose reduction

Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887

IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES

Lee, C., Varnäs, K., & Farde, L. (2013) · doi:10.1002/9781118356845.ch20

Additional file 1 of Multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated 18F-fluorination

Gendron, T., Destro, G., Straathof, N. J. W., Sap, J. B. I., Guibbal, F., Vriamont, C., Caygill, C. H., Atack, J. R., Watkins, A. J., Marshall, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19388907

BindingDB Entry 50009300: Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA

BindingDB (2021) · UC San Diego · doi:10.7270/q2vd72wn

BindingDB Entry 50007820: Design and Identification of a Novel, Functionally Subtype Selective GABA

BindingDB (2021) · UC San Diego · doi:10.7270/q2hq437d

Preclinical and clinical pharmacology of TPA023B, a GABA A receptor α2/α3 subtype-selective partial agonist

Atack, J. R., Hallett, D. J., Tye, S. J., Wafford, K. A., Ryan, C. N., Bohorquez, S. M. S., Eng, W., Gibson, R., Burns, H. D., Dawson, G., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109354928 · Cited by 63 · see citing works

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188 · see citing works

In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2/α3/α5 Subtype Selective γ-Aminobutyric Acid–A Partial Agonist

Laere, K. V., Bormans, G. M., Bohorquez, S. M. S., de Groot, T., Dupont, P. J., Lepeleire, I. D., Hoon, J. N. J. M. D., Mortelmans, L. A., Hargreaves, R. J., Atack, J. R., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.021 · Cited by 23 · see citing works

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA _A α _2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · see citing works

GABAA Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics

Atack, J. R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_30 · Cited by 71 · see citing works